PubMed Health⌕ Search

PubMed · 11670185

Structural Diversity in Monomeric Cadmium Phenoxides.

Abstract

Three monomeric Cd(II) phenoxide complexes have been prepared by reacting Cd[N(SiMe(3))(2)](2) with 2 equiv of 2,6-disubstituted phenols bearing sterically bulky tert-butyl or phenyl groups. The strongly coordinating solvents THF, tetrahydrothiophene (THT), and pyridine used for these reactions were incorporated into the metal's coordination sphere, leading to complexes with a general formulation of Cd(O-2,6-R(2)C(6)H(3))(2)(solv)(2)(-)(3). The Cd complexes obtained have been characterized crystallographically and have been found to adopt differing solid-state geometries. The X-ray crystal structure of Cd(O-2,6-(t)BuC(6)H(3))(2)(THF)(2), 1, previously reported by Buhro, displayed unusual square-planar coordination of the metal center. Complex 2, Cd(O(t)BuC(6)H(3))(2)(THT)(2), has been found to take on the same square-planar geometry, even with the more strongly donating thioether ligand. Alternatively, complex 3, Cd(O-2,6-Ph(2)C(6)H(3))(2)(THF)(2), has been found to adopt distorted-tetrahedral geometry, quite similar to its zinc congener. The O(1)-Cd-O(2) angle between the phenoxide ligands in 3 is 150.1(2) degrees, and the angle between the ether ligands is 83.1(3) degrees. When the strongly basic solvent pyridine was used, a five-coordinate complex 4, Cd(O-2,6-(t)BuC(6)H(3))(2)(py)(3), was isolated. This complex 4 is best described as having trigonal bipyramidal geometry with the phenoxide ligands and one pyridine defining the equatorial plane and two axial pyridine ligands having an angle of 169.7(2) degrees. The angle between the phenoxide ligands in 4 is 156.1(2) degrees. These complexes 1-4 have also been characterized in noncoordinating solvent solutions by (1)H, (13)C, and (113)Cd NMR spectroscopy and have been found to contain labile donor ligands. Preliminary studies indicate that, in a noncoordinating solvent, a rapid equilibrium exists between species with and without coordinated donor solvent ligands.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Donald J. Darensbourg, Sharon A. Niezgoda, Joseph H. Reibenspies, Jennifer D. Draper. 1997-12-03. Structural Diversity in Monomeric Cadmium Phenoxides.. https://doi.org/10.1021/ic971002w

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗